Web Results

law.justia.com/cases/new-jersey/supreme-court/1999/a-16-98-opn.html

Saray Perez, et al. v. Wyeth Laboratories, Inc., et al. Annotate this Case. SYLLABUS. (This syllabus is not part of the opinion of the Court. It has been prepared by the Office of the Clerk for the convenience of the reader. It has been neither reviewed nor approved by the Supreme Court. Please note that, in the interests of ...

www.wlf.org/litigating/case_detail.asp?id=630

On February 22, 2011, the U. S. Supreme Court held that a federal law expressly preempts all state-law products liability suits challenging the design of widely administered childhood vaccines, which the Food and Drug Administration (FDA) has already determined to be safe and effective. The decision was a victory for the ...

www.natlawreview.com/article/perdue-v-wyeth-pharmaceuticals-inc-triple-knockout-pre-emption-and-innovator

Sep 9, 2016 ... See Sara Perdue, as Executor of the Estate of Marjorie Newton v. Wyeth Pharmaceuticals, Inc., et al., Civil Action No. 4:15-cv-00208-FL, 2016 U.S. Dist. LEXIS 94636 (E.D.N.C. Jul. 20, 2016). Amiodarone/Cordarone® is a prescription medication approved by the FDA as a treatment of last resort for ...

www.europeanurology.com/article/S0302-2838(12)00315-6/pdf

Mar 13, 2012 ... Background: Patients with urgency urinary incontinence (UUI) due to overactive bladder (OAB) refractory to oral antimuscarinics have limited therapeutic options. OnabotulinumtoxinA appears to be an effective new treatment. Objective: Assess disease-specific quality-of-life outcomes and general health– ...

link.springer.com/content/pdf/10.1007/s10120-006-0385-4.pdf

were more likely to undergo R0 gastrectomy (50% vs 30%; c2. = 2.064; DF1 ... A.N. Hopper et al.: Value of ulcer surveillance gastroscopy. Patients and methods . GU cancer group. Between October 1, 1995, and September 30, 2003,. 25 579 EGDs ..... Mountford RA, Brown P, Salmon PR, Alvarenga C, Neumann. CS, Read ...

www.eje-online.org/content/166/2/307.full.pdf

Tanner stage IV or V, whose ages ranged between 11.9 and 17.9 years. Results: High prevalence ... et al. (5) did not find a significant difference in glycaemic control and insulin doses in hyperandrogenic and non- hyperandrogenic women with T1DM. ...... This work was financially supported by the Wyeth Foundation and in.

pubmedcentralcanada.ca/pmcc/articles/PMC4602541

Jan 16, 2015 ... Monitoring Editor: Elaine Alvarenga de Almeida Carvalho. ... H. influenzae was more (27.4% vs 20.8%) and S. pneumoniae less (17.1% vs 25.5%) frequently observed in vaccinated (≥2 PCV7 doses or ≥1 PCV7 dose at >1 year of age) versus unvaccinated ..... Abdelnour A, Soley C, Guevara S, et al.

www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462011000100016

The diagnostic criteria for FTLD varied from study to study, since 37.9% used the Lund-Manchester criteria, 17.2% used the criteria by Neary et al.8 20.7% .... Jerson Laks has been a lecturer, and worked as a consultant and in clinical trials with Apsen, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Novartis, and Wyeth- Whitehall.

europepmc.org/articles/pmc5404361

Jan 3, 2017 ... For example, DTwP vaccines manufactured by Pasteur Mérieux, Behring, Wyeth- Lederle, and SmithKline Beecham had efficacies of 92% to 98%, but a .... Maria Carollo et al. found that no matter which kind of aP vaccines were used, 5 y after primary vaccination, the percentage of children with IgG-PT ...